Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ: RCKT )

10.56 -0.15 (-1.37%)
Streaming Delayed Price Updated: 12:57 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Analyst Ratings for Rocket Pharmaceuticals
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analyst Ratings for Rocket Pharmaceuticals
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
4 Analysts Have This to Say About Rocket Pharmaceuticals
Within the last quarter, Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings: 
Via Benzinga
Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor
Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023. 
Via Benzinga
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, STOR, RCKT, RCOR
Via ACCESSWIRE
Why Is Renovacor (RCOR) Stock Up 18% Today?
Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal. 
Via InvestorPlace
Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases
Via Benzinga
RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
From Rocket Pharmaceuticals, Inc. and Renovacor, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
  Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up... 
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
Rocket Pharmaceuticals: Q2 Earnings Insights
  Rocket Pharmaceuticals (NASDAQ:RCKT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Why Jim Cramer Says This Stock Is 'Definitely A Buy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is with Tellurian Inc. (NYSE: TELL). 
Via Benzinga
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Analyst Ratings for Rocket Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.